Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric AS03-adjuvanted H5N1 vaccine immunogenicity and safety trial
2012-001683-29Phase 2
- Sponsor
- GSK
- Start
- Jun 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted in Influenza A H5N1 infection (H5N1) (2 arms), sponsored by GSK. Primary endpoints: Immunogenicity with respect to components of the investigational vaccine and Seroprotection and seroconversion response against A/Indonesia/5/2005.
02
Drugs
Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on 2012-001683-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001683-29.